Previous close | 0.8170 |
Open | 0.8000 |
Bid | 0.7698 x 200 |
Ask | 0.7751 x 200 |
Day's range | 0.7700 - 0.8147 |
52-week range | 0.6700 - 3.1300 |
Volume | |
Avg. volume | 796,340 |
Market cap | 59.857M |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.4000 |
Earnings date | 08 Aug 2024 - 12 Aug 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 11.67 |
SOUTH SAN FRANCISCO, Calif., May 09, 2024--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer, today reported financial results for the first quarter ended March 31, 2024 and provided a business update.
SOUTH SAN FRANCISCO, Calif., May 06, 2024--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer, today announced that the Compensation Committee of the company’s Board of Directors granted two employees nonqualified stock options to purchase 164,000 shares of its common stock with an exercise price of $0.84 per share, which is equal to the closing price of Kezar’s c
In this article, we will take a look at the 13 best penny stocks to buy according to billionaire Ken Griffin. To see more such companies, go directly to 5 Best Penny Stocks to Buy According to Billionaire Ken Griffin. The markets were off to an impressive start in 2024, driven by expectations that the […]